{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:25:05Z","timestamp":1783398305745,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1916-9","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T13:26:14Z","timestamp":1558617974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial"],"prefix":"10.1186","volume":"21","author":[{"name":"for the Paediatric Rheumatology International Trials Organisation (PRINTO)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Foeldvari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e0s","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Vojinovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav","family":"Chasnyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke","family":"Dehoorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Panaviene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Su\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valda","family":"Stanevicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kobusinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogna","family":"Dobrzyniecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Nikishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Bader-Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavla","family":"Dole\u017ealov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Job-Deslandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrida","family":"Rumba-Rozenfelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Wulffraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.","family":"Bukowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-7782","authenticated-orcid":false,"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,23]]},"reference":[{"issue":"9783","key":"1916_CR1","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138\u201349.","journal-title":"Lancet"},{"issue":"9563","key":"1916_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767\u201378.","journal-title":"Lancet"},{"issue":"2","key":"1916_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112\u20137.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"1916_CR4","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"1","key":"1916_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","volume":"77","author":"HI Brunner","year":"2018","unstructured":"Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-Perez N, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77(1):21\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1916_CR6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"1916_CR7","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395.","journal-title":"N Engl J Med"},{"issue":"6","key":"1916_CR8","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","volume":"73","author":"G Horneff","year":"2014","unstructured":"Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, Dehoorne J, Panaviene V, Susic G, Stanevica V, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73(6):1114\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1916_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810\u201320.","journal-title":"N Engl J Med"},{"issue":"25","key":"1916_CR10","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406.","journal-title":"N Engl J Med"},{"issue":"9636","key":"1916_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383\u201391.","journal-title":"Lancet"},{"issue":"4","key":"1916_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465\u201382.","journal-title":"Arthritis Care Res"},{"issue":"11","key":"1916_CR13","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/acr.22657","volume":"67","author":"R Burgos-Vargas","year":"2015","unstructured":"Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Kalabic J, Goss S, Unnebrink K, Anderson JK. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res. 2015;67(11):1503\u201312.","journal-title":"Arthritis Care Res"},{"issue":"34","key":"1916_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20340","volume":"20","author":"J Shepherd","year":"2016","unstructured":"Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1\u2013222.","journal-title":"Health Technol Assess"},{"issue":"11","key":"1916_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. New England J Med. 2000;342(11):763\u20139.","journal-title":"New England J Med"},{"issue":"5","key":"1916_CR16","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496\u2013504.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1916_CR17","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.3899\/jrheum.110145","volume":"38","author":"MH Otten","year":"2011","unstructured":"Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, et al. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010. J Rheumatol. 2011;38(10):2258\u201363.","journal-title":"J Rheumatol"},{"issue":"5","key":"1916_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/ard.2007.087411","volume":"68","author":"FH Prince","year":"2009","unstructured":"Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68(5):635\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1916_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3899\/jrheum.150430","volume":"43","author":"T Constantin","year":"2016","unstructured":"Constantin T, Foeldvari I, Vojinovic J, Horneff G, Burgos-Vargas R, Nikishina I, Akikusa JD, Avcin T, Chaitow J, Koskova E, et al. Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J Rheumatol. 2016;43(4):816\u201324.","journal-title":"J Rheumatol"},{"issue":"6","key":"1916_CR20","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1136\/adc.2010.188946","volume":"96","author":"N Ruperto","year":"2011","unstructured":"Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child. 2011;96(6):596\u2013601.","journal-title":"Arch Dis Child"},{"issue":"7","key":"1916_CR21","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/acr.20497","volume":"63","author":"CA Wallace","year":"2011","unstructured":"Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63(7):929\u201336.","journal-title":"Arthritis Care Res"},{"issue":"7","key":"1916_CR22","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202\u20139.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1916_CR23","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3899\/jrheum.091474","volume":"37","author":"G Filocamo","year":"2010","unstructured":"Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B, Consolaro A, Magni-Manzoni S, Galasso R, Varnier GC, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol. 2010;37(7):1534\u201341.","journal-title":"J Rheumatol"},{"issue":"4","key":"1916_CR24","first-page":"S1","volume":"19","author":"N Ruperto","year":"2001","unstructured":"Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, Tortorelli A, Landgraf JM, Singh G, Martini A, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol. 2001;19(4 Suppl 23):S1\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1916_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658\u201366.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1916_CR26","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1002\/art.34373","volume":"64","author":"A Consolaro","year":"2012","unstructured":"Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, Pederzoli S, Davi S, Martini A, Ravelli A, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012;64(7):2366\u201374.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1916_CR27","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1136\/annrheumdis-2013-204186","volume":"73","author":"A Consolaro","year":"2014","unstructured":"Consolaro A, Ruperto N, Bracciolini G, Frisina A, Gallo MC, Pistorio A, Verazza S, Negro G, Gerloni V, Goldenstein-Schainberg C, et al. Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis. 2014;73(7):1380\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1916_CR28","first-page":"2055","volume":"31","author":"M Henrickson","year":"2004","unstructured":"Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol. 2004;31(10):2055\u201361.","journal-title":"J Rheumatol"},{"issue":"12","key":"1916_CR29","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3899\/jrheum.110427","volume":"38","author":"KJ Donnithorne","year":"2011","unstructured":"Donnithorne KJ, Cron RQ, Beukelman T. Attainment of inactive disease status following initiation of TNF-alpha inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease. J Rheumatol. 2011;38(12):2675\u201381.","journal-title":"J Rheumatol"},{"issue":"2","key":"1916_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/ard.2010.135731","volume":"70","author":"MH Otten","year":"2011","unstructured":"Otten MH, Prince FH, Ten Cate R, van Rossum MA, Twilt M, Hoppenreijs EP, Koopman-Keemink Y, Oranje AP. de Waard-van der Spek FB, Gorter SL et al: tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective? Ann Rheum Dis. 2011;70(2):337\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1916_CR31","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1002\/art.24777","volume":"60","author":"EH Giannini","year":"2009","unstructured":"Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2794\u2013804.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1916_CR32","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/art.21121","volume":"52","author":"SM Tse","year":"2005","unstructured":"Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum. 2005;52(7):2103\u20138.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1916_CR33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/ard.2007.087593","volume":"68","author":"G Horneff","year":"2009","unstructured":"Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1916_CR34","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s10067-013-2261-z","volume":"32","author":"M Trachana","year":"2013","unstructured":"Trachana M, Pratsidou-Gertsi P, Badouraki M, Haidich AB, Pardalos G. Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure. Clin Rheumatol. 2013;32(8):1191\u20137.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1916_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1546-0096-11-35","volume":"11","author":"M Hooper","year":"2013","unstructured":"Hooper M, Wenkert D, Bitman B, Dias VC, Bartley Y. Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports. Pediatr Rheumatol Online J. 2013;11(1):35.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"1916_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/rheumatology\/keq361","volume":"50","author":"G Horneff","year":"2011","unstructured":"Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford). 2011;50(1):230\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1916_CR37","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/art.27511","volume":"62","author":"P Diak","year":"2010","unstructured":"Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62(8):2517\u201324.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1916_CR38","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2017-212613","volume":"77","author":"T Beukelman","year":"2018","unstructured":"Beukelman T, Xie F, Chen L, Horton DB, Lewis JD, Mamtani R, Mannion MM, Saag KG, Curtis JR. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Ann Rheum Dis. 2018;77(7):1012\u20136.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1916-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1916-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1916-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T23:13:33Z","timestamp":1590102813000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1916-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1916"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1916-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,23]]},"assertion":[{"value":"19 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the relevant regulatory bodies of each country and institution. It was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practices. All patients or their parents\/caregivers provided written consent for participation in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"I. Foeldvari has served on advisory boards with AbbVie, Novartis, Chugai, and Genzyme.T. Constantin has received speaker\u2019s fees from or served as a consultant for AbbVie, Novartis, Pfizer, and Roche.J. Vojinovi\u0107 has received honoraria from AbbVie, Pfizer, TEVA, MSD, and Roche.G. Horneff has received honoraria from Chugai, UCB, Pfizer, AbbVie, Roche, and Novartis.J. Dehoorne has received speaker\u2019s fees from or served as a consultant for AbbVie, Pfizer, and Roche.V. Stanevicha has received consulting fees from AbbVie and Roche and has a partnership with Pfizer.I. Nikishina has received honoraria from AbbVie, Bristol-Myers Squibb, Janssen, MSD, Novartis, Pfizer, and Roche.P. Dole\u017ealov\u00e1 has received speaker\u2019s bureau honoraria from Pfizer, AbbVie, Novartis, Hoffman-La Roche, Medac, Swedish Orphan Biovitrum, Eli Lilly, Sanofi, and Genzyme.R. Pedersen and B. Vlahos are employees of Pfizer, the sponsor of this study, and own company stock.J. Bukowski is a former employee of Pfizer, the sponsor of this study, and may own company stock.A. Martini has received speaker\u2019s bureau and honoraria from Abbott, AbbVie, Amgen, Biogen Idec, Bristol-Myers Squibb, Astellas, Boehringer, Italfarmaco, Janssen, MedImmune, Novartis, Novo Nordisk, Pfizer, Sanofi, Roche, Servier, and Takeda.N. Ruperto has received speaker\u2019s bureau and honoraria from Abbott, AbbVie, Amgen, Biogen Idec, Astellas, Alter, AstraZeneca, Boehringer, Bristol-Myers Squibb, CD-Pharma, Celgene, Crescendo Bioscience, EMD Serono, Hoffman-La Roche, Italfarmaco, Janssen, MedImmune, Medac, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis, Servier, Takeda, and Vertex.The IRCCS Istituto Giannina Gaslini, which is the public hospital where Dr. Ruperto and Prof Martini work as full-time employees, has received contributions to support the research activities of the network of PRINTO () from Abbott, Bristol-Myers Squibb, Francesco Angelini SPA, Glaxo SmithKline, Janssen Biotech Inc., Novartis, Pfizer Inc., Roche, Sanofi Aventis, and Schwarz Biosciences GmbH; this money has been reinvested for the research activities of the hospital in a fully independent manner without any commitment to third parties.V. Chasnyk, V. Panaviene, G. Su\u0161i\u0107, K. Kobusinska, Z. Zuber, B. Dobrzyniecka, B. Bader-Meunier, L. Breda, C. Job-Deslandre, I. Rumba-Rozenfelde, and N. Wulffraat declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"125"}}